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Introduction
Leflunomide is an oral immunomodulatory agent, which is
considered effective for the treatment of rheumatoid
arthritis (RA). Leflunomide is a disease-modifying anti-
rheumatic drug that is approved for treatment of RA, and
radiographical findings indicate that it delays joint damage
[1–4]. Its therapeutic profile closely resembles that of
methotrexate. The latter drug is the most widely used
disease-modifying antirheumatic drug but, despite a
favourable efficiency–toxicity profile, in numerous patients
it is either insufficient or associated with unacceptable
side effects.
In vivo, leflunomide is rapidly converted into its
pharmacologically active metabolite A77 1726 [5]. The
recommended dose of leflunomide for the treatment of RA
patients is 20 mg/day, which produces steady-state serum
levels of A77 1726 of approximately 25–45 µg/ml
COX = cyclo-oxygenase; DHODH = dihydro-orotate dehydrogenase; ELISA = enzyme-linked immunosorbent assay; FCS = foetal calf serum; IL =
interleukin; IL-1Ra = IL-1 receptor antagonist; MMP = matrix metalloproteinase; OA = osteoarthritis; PGE2 = prostaglandin E2; RA = rheumatoid
arthritis; TNF = tumour necrosis factor.
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Abstract
Leflunomide is an immunomodulatory agent used for the
treatment of rheumatoid arthritis. In this study, we investigated
the effect of A77 1726 – the active metabolite of leflunomide –
on the production of IL-1 receptor antagonist (IL-1Ra) by
human synovial fibroblasts and articular chondrocytes. Cells
were incubated with A77 1726 alone or in combination with
proinflammatory cytokines. IL-1Ra production was determined
by ELISA. A77 1726 alone had no effect, but in the presence
of IL-1β or tumour necrosis factor-α it markedly enhanced the
secretion of IL-1Ra in synovial fibroblasts and chondrocytes.
The effect of A77 1726 was greatest at 100 µmol/l. In synovial
fibroblasts and de-differentiated chondrocytes, A77 1726 also
increased IL-1β-induced IL-1Ra production in cell lysates.
Freshly isolated chondrocytes contained no significant amounts
of intracellular IL-1Ra. A77 1726 is a known inhibitor of
pyrimidine synthesis and cyclo-oxygenase (COX)-2 activity.
Addition of exogenous uridine did not significantly modify the
effect of A77 1726 on IL-1Ra production, suggesting that it
was not mediated by inhibition of pyrimidine synthesis. Indo-
methacin increased IL-1β-induced IL-1Ra secretion in synovial
fibroblasts and de-differentiated chondrocytes, suggesting that
inhibition of COX-2 may indeed enhance IL-1β-induced IL-1Ra
production. However, the stimulatory effect of indomethacin
was consistently less effective than that of A77 1726.
A77 1726 increases IL-1Ra production by synovial fibroblasts
and chondrocytes in the presence of proinflammatory
cytokines, and thus it may possess chondroprotective effects.
The effect of A77 1726 may be partially mediated by inhibition
of COX-2, but other mechanisms likely concur to stimulate IL-
1Ra production.
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(75–115 µmol/l) [6]. Although the precise mode of action
of leflunomide in vivo remains elusive, A77 1726 has been
shown  in vitro to inhibit reversibly dihydro-orotate de-
hydrogenase (DHODH), which catalyzes a rate-limiting
step in the de novo synthesis of pyrimidines [7,8]. The
inhibition of DHODH activity by A77 1726 might explain
part of its mechanism of action in suppressing inflam-
mation. Indeed, many effects of A77 1726 can be reversed
by exposing target cells to the product of DHODH activity,
namely uridine. Leflunomide is a potent noncytotoxic
inhibitor of the proliferation of stimulated B and T
lymphocytes, which depend on de novo pyrimidine
synthesis to fulfill their metabolic needs [4,5]. Furthermore,
leflunomide blocks tumour necrosis factor (TNF)-α-
mediated cellular responses in T cells by inhibiting nuclear
factor-κB – a mechanism that also depends on pyrimidine
biosynthesis [9,10]. In addition, A77 1726 exerts a direct
inhibitory effect on cyclo-oxygenase (COX)-2 activity, both
in vitro and in vivo [11,12]. Finally, it has been reported
that, at higher concentrations, A77 1726 inhibits different
types of receptor and nonreceptor tyrosine kinases that are
involved in cytokine and growth factor signalling [13–15].
RA is characterized by synoviocyte proliferation and
infiltration of inflammatory cells, such as lymphocytes and
macrophages, into the joint. Local release of pro-
inflammatory mediators and metalloproteinases causes
joint cartilage destruction and leads to the perpetuation of
joint inflammation. Potential direct anti-inflammatory
effects of A77 1726 on joint cells are thus of interest
because of their relevance to the effectiveness of lefluno-
mide in treating RA and other cartilage-damaging
diseases. In a previous study, A77 1726 was found to
inhibit the expression of monocyte-activating factor at the
surface of T lymphocytes, which in turn decreased the
activation of monocyte/macrophages, and thus their
production of IL-1β and matrix metalloproteinase (MMP)-1
[16]. A further study showed that A77 1726 inhibits the
production of prostaglandin E2 (PGE2), MMP-1 and IL-6 in
human synovial fibroblasts [12]. The inhibition of MMP-1
and IL-6 production was due to the well known inhibitory
effect of A77 1726 on pyrimidine synthesis, because it
was reversed by the addition of uridine. PGE2 production
appeared to be inhibited by the direct action of A77 1726
on COX-2. More recently, A77 1726 was reported to
decrease TNF-α, intercellular adhesion molecule-1 and
COX-2 expression in synovial macrophages [17]. A77 1726
also inhibited IL-1β, TNF-α, nitric oxide and MMP-3
production in activated human synovial tissue cultures [18].
Thus, several studies indicate that A77 1726 inhibits the
production of proinflammatory mediators by synovial
fibroblasts.
Methotrexate also exhibits many of these effects, and in
addition it has been shown to stimulate the synthesis of
the anticatabolic factor IL-1 receptor antagonist (IL-1Ra)
[19]. Increased production of IL-1Ra by joint cells in
response to A77 1726 might potentially be beneficial by
contributing to prevent joint damage in inflammatory
arthropathies such as RA. However, it has not been
determined whether A77 1726 has direct effects on the
production of this anti-inflammatory molecule in synovial
fibroblasts. Furthermore, potential direct effects of
A77 1726 on articular cartilage and chondrocytes have
not yet been examined.
In the present study we investigated the effect of
A77 1726 on the production of IL-1Ra in human synovial
fibroblasts, as well as in freshly isolated and in subcultured
human articular chondrocytes.
Methods
Materials
Cell culture reagents were obtained from Gibco (Life
Technologies AG, Basel, Switzerland). A77 1726
(HMR1726) – the active metabolite of leflunomide – was
generously provided by Aventis Pharma (Frankfurt am
Main, Germany). A77 1726 was dissolved as a 10 mmol/l
stock solution in phosphate-buffered saline. Recombinant
human IL-1β and TNF-α were purchased from R&D
Systems (Abingdon, UK). Indomethacin was obtained
from Sigma Fine Chemicals (St. Louis, MO, USA).
Cell isolation and culture
Synovium was obtained from patients undergoing joint
replacement (knee or hip prosthetic surgery) for osteo-
arthritis (OA) or RA. Cartilage was obtained from patients
undergoing joint replacement (knee or hip prosthetic
surgery) for OA or broken femoral neck (normal adult
cartilage), or from children undergoing spinal surgery for
scoliosis (vertebral posterior joints, normal paediatric
cartilage). Synovial fibroblasts and chondrocytes were
isolated by collagenase digestion as reported previously
[20,21] and cultured in Dulbecco’s modified eagle
medium supplemented with L-glutamine, streptomycin,
penicillin and 10% foetal calf serum (FCS). Synovial
fibroblasts were used between passages 1 and 7, as
indicated. Primary chondrocytes were used directly after
isolation from cartilage and de-differentiated chondrocytes
were used between passages 1 and 7, as indicated. In
total, the effect of A77 1726 was evaluated in 15 indepen-
dent cultures of synovial fibroblast, 18 independent
cultures of freshly isolated primary chondrocytes and 13
independent cultures of de-differentiated chondrocytes.
Cells were plated in 96-well plates (40,000 cells per well)
and used 24 hours after plating. To reduce nonspecific
effects of FCS, the cells were incubated with the various
agents in low-serum (0.5% FCS) medium. The cells were
preincubated with A77 1726 or indomethacin for 2 hours
before stimulation with IL-1β or TNF-α for 48 hours. In
some experiments, uridine (50 or 200 µmol/l) was added
30 min before A77 1726.R183
Assessment of IL-1 receptor antagonist and
prostaglandin E2 production
Culture supernatants were collected and stored at –20°C.
Cell lysates were obtained by adding fresh medium
containing 1% NP-40 to the cells. The concentrations of
IL-1Ra in supernatants and lysates were determined by
sandwich ELISA, as previously described [22]. The
sensitivity of this assay is 78 pg/ml. Concentrations of
PGE2 in supernatants were determined as previously
described [12].
Statistical analysis
The statistical significance of differences was calculated
using analysis of variance. P < 0.05 was considered
statistically significant.
Results
Impact of A77 1726 on production of IL-1 receptor
antagonist
We first investigated the effect of A77 1726 on IL-1Ra
production in human synovial fibroblasts. Although
A77 1726 alone had no significant effect, it markedly
stimulated IL-1Ra secretion in the presence of IL-1β
(Fig. 1a). The effect of A77 1726 was dose-dependent
and highest at 100 µmol/l. Higher doses of A77 1726
(200 or 300 µmol/l) decreased cell viability (data not shown).
In human articular chondrocytes A77 1726 also enhanced
IL-1Ra secretion in the presence of IL-1β but had no effect
on its own (Fig. 1b,c). In subcultured de-differentiated
chondrocytes, A77 1726 exhibited a marked dose-
dependent effect on IL-1β induced IL-1Ra production,
which was greatest at 100 µmol/l (Fig. 1b). In freshly
isolated primary chondrocytes, A77 1726 used at
100 µmol/l also enhanced secretion of IL-1Ra induced by
IL-1β (Fig. 1c). However, the levels of IL-1Ra secreted by
freshly isolated chondrocytes on stimulation with
A77 1726 and IL-1β were consistently much lower than
those produced by stimulated synovial fibroblasts or
subcultured de-differentiated chondrocytes. Furthermore,
in freshly isolated chondrocytes, the stimulatory effect of
A77 1726 on IL-1β-induced IL-1Ra production was more
difficult to reproduce than in the two other cell types, and
was significant only in about two-thirds of all experiments
performed. Finally, when using A77 1726 at 50 µmol/l, we
were unable to observe a consistent effect on IL-1Ra
production in primary chondrocytes.
In parallel to enhancing the production of secreted IL-1Ra,
A77 1726 also increased the amount of IL-1Ra present in
cell lysates of synovial fibroblasts stimulated with IL-1β
(Fig. 2a). IL-1β alone stimulated the production of intra-
cellular IL-1Ra in these cells and this effect was markedly
enhanced by A77 1726. Cell lysates of primary human
chondrocytes contained undetectable or very low levels of
IL-1Ra, even after stimulation with A77 1726 and IL-1β
(data not shown). However, the levels of IL-1Ra in
chondrocyte lysates increased with the number of
passages; in subcultured, de-differentiated chondrocytes,
IL-1β stimulated slightly the production of intracellular
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Figure 1
A77 1726 increases IL-1 receptor antagonist (IL-1Ra) secretion in
human synovial fibroblasts and articular chondrocytes in the presence
of IL-1β. (a) Human osteoarthritis (OA) synovial fibroblasts (passage 2)
and (b) de-differentiated human OA articular chondrocytes
(passage 7) were stimulated (closed symbols) or not (open symbols)
with 1 ng/ml IL-1β alone or in combination with 50 µmol/l or
100 µmol/l A77 1726 for 48 hours. (c) Freshly isolated normal human
articular chondrocytes were stimulated (black columns) or not (white
columns) with 100 µmol/l A77 1726 alone or in combination with
1 ng/ml IL-1β for 48 hours. A77 1726 was added 2 hours before
stimulation with IL-1β. IL-1Ra concentrations in culture supernatants
were measured using ELISA. Results are expressed as means ± SEM
for three determinations in a representative experiment. Similar results
were obtained with cells from three different donors (three OA
samples) for synovial fibroblasts and three different donors (three OA
samples) for de-differentiated chondrocytes. On freshly isolated
chondrocytes, a stimulatory effect of A77 1726 was observed in cells
from 12 (five normal adult, six OA and one normal paediatric sample)
out of 18 different donors. *P < 0.05 versus control; &P < 0.05 versus
IL-1β alone.
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*IL-1Ra, and A77 1726 considerably enhanced this effect
(Fig. 2b).
We next investigated whether the stimulatory effect of
A77 1726 was restricted to IL-1Ra production induced by
IL-1β, or whether it could also be observed in the
presence of other proinflammatory cytokines, such as
TNF-α. As in the case for IL-1β, A77 1726 markedly and
dose-dependently increased IL-1Ra secretion in synovial
fibroblasts and chondrocytes in the presence of TNF-α
(Fig. 3). The effect of A77 1726 was highest at
100 µmol/l. Furthermore, stimulation of IL-1Ra secretion
by A77 1726 in human synovial fibroblasts was also
dependent on the dose of IL-1β or TNF-α added (Fig. 4).
Finally, suboptimal doses of IL-1β and TNF-α had additive
effects on IL-1Ra production, both in the presence and in
the absence of A77 1726 (Fig. 4).
Mechanisms underlying the stimulatory effect of
A77 1726 on IL-1 receptor antagonist production
In order to determine whether stimulation of IL-1Ra
production by A77 1726 might be related to its well known
inhibition of pyrimidine synthesis, we tested whether
uridine could reverse the induction of IL-1Ra expression
by A77 1726. However, uridine (50 and 200 µmol/l) had
no impact on the enhancement of IL-1Ra secretion by
A77 1726 in IL-1β-treated synovial fibroblasts, or de-
differentiated or primary chondrocytes (data not shown).
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Figure 2
A77 1726 increases the production of intracellular IL-1 receptor
antagonist (IL-1Ra) in human synovial fibroblasts and de-differentiated
articular chondrocytes. (a) Human osteoarthritis (OA) synovial
fibroblasts (passage 1) and (b) de-differentiated human OA articular
chondrocytes (passage 5) were stimulated (black columns) or not
(white columns) with 100 µmol/l A77 1726 alone or in combination
with 1 ng/ml IL-1β for 48 hours. A77 1726 was added 2 hours before
stimulation with IL-1β. IL-1Ra concentrations in cell lysates were
measured by ELISA. Results are represented as means ± SEM for
three determinations in a representative experiment. Similar results
were obtained with cells from five different donors (four OA and one
rheumatoid arthritis sample) for synovial fibroblasts and two different
donors (two OA samples) for de-differentiated chondrocytes.
*P < 0.05 versus control; &P < 0.01 versus IL-1β alone.
(a)
(b)
&
*
&
*
Figure 3
A77 1726 increases IL-1 receptor antagonist (IL-1Ra) secretion in
human synovial fibroblasts and articular chondrocytes in the presence
of tumour necrosis factor (TNF)-α. (a) Human osteoarthritis (OA)
synovial fibroblasts (passage 2) and (b) de-differentiated human OA
articular chondrocytes (passage 7) were stimulated (closed symbols)
or not (open symbols) with 10 ng/ml TNF-α alone or in combination
with 50 µmol/l or 100 µmol/l A77 1726 for 48 hours. A77 1726 was
added 2 hours before stimulation with TNF-α. IL-1Ra concentrations in
culture supernatants were measured by ELISA. Results are
represented as means ± SEM of three determinations in a
representative experiment. A similar dose dependency was observed in
cells obtained from three different donors (three OA samples) for
synovial fibroblasts and three different donors (three OA samples) for
de-differentiated chondrocytes. *P < 0.001 versus control; &P < 0.001
versus TNF-α alone.
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*We previously observed inhibition of COX-2 activity and
of PGE2 production by A77 1726 in human synovial
fibroblasts, and we therefore investigated whether
A77 1726 could also inhibit PGE2 production in human
articular chondrocytes. A77 1726 at 100 µmol/l completely
blocked the production of PGE2 induced by IL-1β in
human synovial fibroblasts, as well as in de-differentiated
and in freshly isolated chondrocytes (Fig. 5). A similar
inhibition of PGE2 synthesis was observed in the presence
of 5 µg/ml indomethacin in the three cell types. We
repeatedly observed much lower levels of IL-1β-induced
PGE2 production in freshly isolated primary chondrocytes
than in de-differentiated chondrocytes and synovial
fibroblasts (Fig. 5).
If the enhancing effect of A77 1726 on IL-1β-induced
IL-1Ra production was due to inhibition of COX-2 activity,
then the effect of indomethacin on IL-1Ra production
should be comparable to that of A77 1726. Indeed,
indomethacin increased IL-1β-induced IL-1Ra secretion in
human synovial fibroblasts and in de-differentiated
chondrocytes (Fig. 6a,b), suggesting that the inhibition of
COX-2 enhanced IL-1Ra production in the presence of
IL-1β in these cells. However, because the stimulatory
effect of indomethacin was consistently less effective than
that of A77 1726, additional mechanisms account for the
increased IL-1Ra production in response to the latter
compound. Finally, in agreement with the low levels of
PGE2 produced by freshly isolated chondrocytes, which
are suggestive of low COX-2 expression or activity,
indomethacin had no significant effect on IL-1β-induced
IL-1Ra production in these cells (Fig. 6c).
Discussion
In the present study we investigated the effect of the
active metabolite of leflunomide – A77 1726 – on the
production of IL-1Ra by human joint cells. We observed
that A77 1726, while having no effect alone, markedly
enhanced the secretion of IL-1Ra in the presence of IL-1β
or TNF-α in synovial fibroblasts and articular chondrocytes.
The effect of A77 1726 was maximal at 100 µmol/l – a
dose that lies within the range of plasma concentrations
that may be observed in leflunomide-treated patients
[6,23]. Because IL-1Ra has been shown to exert
chondroprotective effects, our observations suggest that
in the presence of proinflammatory cytokines, which are
present in significant amounts in inflamed joints, A77 1726
might exert a beneficial effect by increasing the local
production of this anti-inflammatory mediator by joint cells.
IL-1Ra, which was initially discovered for impeding the
binding of IL-1 to lymphoma cells, is produced in four
different isoforms, one secreted and three intracellular,
which are derived from the same gene [24,25]. The exact
biological functions of the different IL-1Ra isoforms are
still not clear [25–27]. The major role of secreted IL-1Ra is
to block the effects of IL-1 by binding competitively to IL-1
receptor I without inducing signal transduction. The
intracellular isoforms may be released from cells under
certain circumstances, but they have also been suggested
to perform important regulatory roles within cells. Synovial
fibroblasts and de-differentiated chondrocytes produce
both secreted and intracellular IL-1Ra [28], and in these
cells IL-1β-induced IL-1Ra production was enhanced in
culture supernatants and in cell lysates in response to
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Figure 4
Dose dependent and additive effects of IL-1β and tumour necrosis
factor (TNF)-α on IL-1 receptor antagonist (IL-1Ra) secretion in the
presence of A77 1726 in human synovial fibroblasts. (a) Human
osteoarthritis (OA) synovial fibroblasts (passage 4) were stimulated
with various doses of IL-1β, or (b) various doses of TNF-α or with
0.25 ng/ml IL-1β and 1 ng/ml TNF-α together, in the absence (open
symbols) or presence (closed symbols) of 100 µmol/l A77 1726, for
48 hours. A77 1726 was added 2 hours before stimulation with IL-1β.
IL-1Ra concentrations in culture supernatants were measured using
ELISA. Results are represented as means ± SEM of three
determinations in a representative experiment. Similar results were
obtained with cells from three different donors (three OA samples).
*P < 0.05 versus control; &P < 0.05 versus cytokines without
A77 1726.
(a)
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*A77 1726. In contrast, cell lysates of freshly isolated
chondrocytes contained no significant amounts of IL-1Ra,
even after stimulation with IL-1β and A77 1726, which is
consistent with our previous observations [28,29].
In a recent study we observed that over-expression of
either the secreted or the type I intracellular IL-1Ra isoform
similarly protected mice from collagen-induced arthritis,
blocking inflammation and joint damage [30]. In RA,
IL-1Ra has been shown to be one of the most potent
agents available to decrease the progression of joint
destruction [31–33], although its effects on inflammation
and symptoms are frequently considered disappointing. It
is generally considered that a 10- to 100-fold molar
excess of IL-1Ra over IL-1 is required to suppress
completely the biological effects of IL-1, although lower
amounts of IL-1Ra can significantly inhibit IL-1-induced
responses [34]. In the present study, the levels of IL-1Ra
Arthritis Research & Therapy    Vol 6 No 3 Palmer et al.
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Figure 5
A77 1726 inhibits IL-1β-induced prostaglandin E2 (PGE2) production
in human synovial fibroblasts and articular chondrocytes. 
(a) Human osteoarthritis (OA) synovial fibroblasts (passage 1), 
(b) de-differentiated human OA articular chondrocytes (passage 4),
and (c) freshly isolated human OA articular chondrocytes were
stimulated or not (control; white bars) with 1 ng/ml IL-1β (hatched
bars), the combination of 1 ng/ml IL-1β and 100 µmol/l A77 1726
(black bars), or the combination of 1 ng/ml IL-1β and 5 µg/ml
indomethacin (grey bars) for 48 hours. A77 1726 or indomethacin was
added 2 hours before stimulation with IL-1β. PGE2 concentrations in
culture supernatants were measured as described elsewhere [12].
Results are represented as means ± SEM of three determinations in
one representative experiment. Similar results were obtained with cells
from two different donors (two OA samples) for synovial fibroblasts,
three different donors (three OA samples) for de-differentiated
chondrocytes and five different donors (three normal and two OA
samples) for freshly isolated chondrocytes. *P < 0.01 versus control;
&P < 0.01 versus IL-1β.
(a)
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Figure 6
Effect of indomethacin on IL-1 receptor antagonist (IL-1Ra) secretion
in human synovial fibroblasts and articular chondrocytes. 
(a) Human osteoarthritis (OA) synovial fibroblasts (passage 1), 
(b) de-differentiated human OA articular chondrocytes (passage 2),
and (c) freshly isolated human OA articular chondrocytes were
stimulated or not (control; white bars) with 1 ng/ml IL-1β (hatched
bars), the combination of IL-1β and 5 µg/ml indomethacin (gray bars),
or the combination of IL-1β and 100 µmol/l A77 1726 (black bars) for
48 hours. Indomethacin or A77 1726 was added 2 hours before
stimulation with IL-1β. IL-1Ra concentrations in culture supernatants
were measured by ELISA. Results are presented as means ± SEM of
three determinations in a representative experiment. Similar results
were obtained with cells from six different donors (six OA samples) for
synovial fibroblasts, seven different donors (seven OA samples) for de-
differentiated chondrocytes and six different donors (three normal and
three OA samples) for freshly isolated chondrocytes. *P < 0.05 versus
control; &P < 0.05 versus IL-1β alone; **P < 0.001 versus IL-1β alone.
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&produced by synovial fibroblasts and de-differentiated
chondrocytes on stimulation with A77 1726 and IL-1β
usually ranged between equimolar concentrations and a
twofold molar excess of IL-1Ra over IL-1. Even higher
molar ratios of IL-1Ra:IL-1 were obtained when IL-1 was
combined with TNF-α. Although large amounts of IL-1 are
needed to obtain maximal catabolic effects in vitro,
multiple lines of evidence (for example [35]) indicate that
even very low levels of catabolic cytokines, including IL-1,
can synergize to induce substantial effects. In vivo, it is
likely that multiple cytokines present in low amounts act in
synergy to induce proinflammatory and catabolic effects.
Thus, the blockade of low amounts of IL-1 might be
sufficient to decrease such a synergistic effect in vivo. The
increased production of both secreted and intracellular IL-
1Ra, which was observed in joint cells in response to
A77 1726, might therefore be potentially beneficial by
contributing to prevent joint damage in inflammatory
arthropathies such as RA. In this regard, administration of
leflunomide has been shown to limit joint destruction and
improve function scores significantly, and to a greater
degree than with methotrexate, according to at least two
studies [1,36]. The mechanisms that result in this
protection are likely to be multiple. However, a stimulatory
effect on IL-1Ra synthesis might be particularly relevant,
given the important role of IL-1 in joint destruction [37].
We investigated putative pathways involved in mediating
the stimulatory effect of A77 1726 on IL-1Ra production,
first focusing on the known effect of A77 1726 on
pyrimidine synthesis. Addition of exogenous uridine did
not significantly modulate the effect of A77 1726,
suggesting that it was unlikely to be related to the
inhibition of pyrimidine synthesis.
A77 1726 was previously reported to inhibit COX-2 activity
[11]. Also, the findings reported here confirm a previous
report that 100 µmol/l A77 1726 completely blocked
IL-1β-induced PGE2 production in synovial fibroblasts
[12]. Similarly, we observed that A77 1726 inhibited IL-
1β-induced PGE2 production in chondrocytes.
Interestingly, IL-1β triggered production of lower amounts
of PGE2 in freshly isolated chondrocytes than in de-
differentiated chondrocytes, suggesting low levels of
expression and/or activity of COX-2 in these primary cells.
This observation substantiates a recent report, which
described a similar, differentiation stage-dependent
regulation of COX-2 expression and PGE2 production in
rabbit articular chondrocytes [38]. Indomethacin
increased IL-1β-induced IL-1Ra production in synovial
fibroblasts and de-differentiated chondrocytes, suggesting
that inhibition of COX-2 may indeed enhance IL-1Ra
production in the presence of IL-1β in these cells.
However, the stimulatory effect of indomethacin was
repeatedly less potent than that of A77 1726. In addition,
indomethacin did not affect IL-1Ra production in primary
chondrocytes. This observation is consistent with the low
levels of PGE2 produced in these cells, which are
suggestive of low COX-2 expression/activity. It is also in
agreement with a previous study that described a lack of
effect of indomethacin on IL-1Ra production in IL-1-
stimulated OA chondrocytes [39]. Moreover, both in
synovial fibroblasts and in chondrocytes, we observed that
IL-1β-induced PGE2 production was strongly inhibited at
relatively low concentrations (10–50 µmol/l) of A77 1726,
as compared with the higher doses (50–100 µmol/l) that
were required to enhance IL-1Ra production efficiently
(data not shown). The dose dependency of these two
effects thus appeared to be slightly different. Taken
together, these observations strongly suggest that, in
addition to the inhibitory effect of A77 1726 on COX-2
activity and PGE2 production, other mechanisms contribute
to its stimulatory effect on IL-1Ra secretion.
Because high doses of A77 1726 have been reported to
inhibit different types of receptor and nonreceptor tyrosine
kinases [13–15], we assessed whether tyrosine kinase
inhibitors would affect IL-1β-induced IL-1Ra production in
fibroblasts and chondrocytes. Two types of inhibitors were
tested: genistein, a broad range tyrosine kinase inhibitor;
and PP1, a more specific inhibitor of the src family of
tyrosine kinases, the members of which have been
reported to mediate IL-1 signalling in various cell types
[40,41]. Both inhibitors decreased IL-1β-induced IL-1Ra
expression in synovial fibroblasts and chondrocytes (data
not shown). These observations suggest that the increase
in IL-1Ra production observed in the presence of
A77 1726 is unlikely to be due to the inhibition of tyrosine
kinases. Thus, although our findings suggest that part of
the effect of A77 1726 on IL-1Ra production occurs
through the inhibition of COX-2 activity, other unknown
mechanisms, which remain to be characterized, are likely
to be involved.
Conclusion
A77 1726 enhanced the production of IL-1Ra by human
synovial fibroblasts and articular chondrocytes in the
presence of the proinflammatory cytokines IL-1β and
TNF-α. This might explain some of the protective effects
exerted by leflunomide in RA and other cartilage-damaging
diseases.
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